Related Experiment Video

Updated: Apr 6, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.2K

Host genetic variants influencing the clinical course of hepatitis C virus infection

Kentaro Matsuura1,2,3, Yasuhito Tanaka1

  • 1Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.

Journal of Medical Virology
|July 28, 2015
PubMed

Insights

Host genetic factors significantly impact hepatitis C virus (HCV) infection outcomes. Understanding these genetic influences is key for personalized treatment and monitoring disease progression.

Area of Science:

  • Genetics
  • Hepatology
  • Virology

Background:

  • Hepatitis C virus (HCV) infection exhibits diverse clinical trajectories influenced by viral, host, and environmental factors.
  • Genome-wide association studies have identified specific host genetic factors affecting HCV infection outcomes.
  • IFNL3-IFNL4 variants are notably linked to interferon-based treatment response and spontaneous clearance of acute HCV.

Purpose of the Study:

  • To explore the role of host genetic factors in the clinical course of hepatitis C virus infection.
  • To highlight genetic associations with spontaneous clearance, treatment efficacy, disease progression, and hepatocellular carcinoma risk.

Main Methods:

  • Review of genome-wide association studies (GWAS) and genetic association studies.
  • Analysis of genetic variants in IFNL3-IFNL4, HLA class II loci, apoptosis-related genes (RNF7, TULP1, MERTK), and DEPDC5/MICA.

Main Results:

  • IFNL3-IFNL4 variants strongly predict response to interferon-based therapy and spontaneous clearance of acute HCV.
  • Genetic factors influence hepatitis activity and disease progression in chronic HCV infection.
  • Specific polymorphisms are associated with fibrosis progression and HCV-related hepatocellular carcinoma.

Conclusions:

  • Host genetic factors play a critical role in determining the clinical course of HCV infection.
  • Understanding these genetic determinants is crucial for developing personalized treatment strategies and improving surveillance for disease progression and hepatocellular carcinoma.

Keywords:
GWASHCCHCVfibrosisspontaneous clearance

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
Reverse Genetics to Engineer Positive-Sense RNA Virus Variants15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

2.1K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
116
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
42
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
102
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
203
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
131